Exploring the signal pathway regulating vascular endothelial growth factor production in diabetic retinopathy

doi:10.3877/cma.j.issn.2095-2007.2018.05.007

Abstract

Abstract:

Diabetic retinopathy (DR), as the most serious microvascular complication of diabetes mellitus (DM) in the eye, has become the leading cause of blindness in working-age adults worldwide. Vascular endothelial growth factor (VEGF) has been shown to play an important role in the formation of neovascularization in DR. Increased expression of VEGF leads to pathological changes such as neovascularization, increased vascular endothelial cell permeability, decreased pro-apoptotic protein inhibition, and various other inflammatory mediators were activated. Therefore, exploring various signaling pathways that regulate VEGF production contributes to a deeper understanding of the relationship between these pathological changes. This article reviews the various signaling pathways in DR that regulate VEGF production and their association with DR.

Key words: Diabetic retinopathy, Vascular endothelial growth factor, Pathogenesis, Signaling pathways

Wei He, Qi Huang, Xi Yu, Hongbin Lv. Exploring the signal pathway regulating vascular endothelial growth factor production in diabetic retinopathy[J]. Chinese Journal of Ophthalmologic Medicine(Electronic Edition), 2018, 08(05): 235-240.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhykyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2007.2018.05.007

https://zhykyxzz.cma-cmc.com.cn/EN/Y2018/V08/I05/235

References 53

[1]	Wang CC, Reusch JE. Diabetes and cardiovascular disease: changing the focus from glycemic control to improving long－term survival[J]. The American Journal of Cardiology, 2012, 110(9) : 58B-68B.
[2]	Sorrentino FS, Allkabes M, Salsini G, et al. The importance of glial cells in the homeostasis of the retinal microenvironment and their pivotal role in the course of diabetic retinopathy[J]. Life sciences, 2016, 162 : 54-59.
[3]	Kowluru RA, Chan PS. Oxidative stress and diabetic retinopathy[J]. Experimental Diabesity Research. 2007, 2007 (3) : 43603.
[4]	Tang J, Kern TS. Inflammation in diabetic retinopathy[J]. Progress in retinal and eye research, 2011, 30(5) : 343-358.
[5]	Penn JS, Madan A, Caldwell RB, et al. Vascular endothelial growth factor in eye disease[J]. Progress in retinal and eye research, 2008, 27(4) : 331-371.
[6]	Rask－Madsen C, King GL. Kidney complications: factors that protect the diabetic vasculature[J]. Nature medicine, 2010, 16 (1) : 40-41.
[7]	陈娟, 吕红彬. 抗VEGF药物在糖尿病性视网膜病变治疗中的应用[J]. 眼科新进展，2014，34(4)：397-400.
[8]	李峰, 隋桂琴, 车松天，等. 从糖尿病性视网膜病变发病机制看抗VEGF药物作用[J]. 中国实用眼科杂志，2011，29(1)：18-20.
[9]	Senger DR. Vascular endothelial growth factor: much more than an angiogenesis factor[J]. Molecular biology of the cell, 2010, 21(3) : 377-379.
[10]	Shibuya M. Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti－ and Pro－Angiogenic Therapies[J]. Genes & cancer, 2011, 2(12) : 1097-1105.
[11]	李春深, 常柏, 苗戎，等. 抵挡汤早期干预对糖尿病大鼠视网膜VEGF和PKC基因表达的影响[J]. 北京中医药大学学报，2012，35(8)：543-548.
[12]	张伟丽, 惠汝太. VEGF及其受体在动脉粥样硬化中的作用[J]. 中国分子心脏病学杂志，2005，5(3)：568-573.
[13]	郑志. 活性氧在糖尿病性视网膜病变中作用机制及干预研究[D]. 上海：上海交通大学，2007：15，46－47.
[14]	Behl T, Kotwani A. Exploring the various aspects of the pathological role of vascular endothelial growth factor (VEGF) in diabetic retinopathy[J]. Pharmacological research, 2015, 99：137-148.
[15]	贾薇, 袁中华. 动脉粥样硬化中的4个PKC相关酶[J]. 中国病理生理杂志. 2007，23(7)：1442-1445.
[16]	Brownlee M. The pathobiology of diabetic complications: a unifying mechanism[J]. Diabetes, 2005, 54(6) : 1615-1625.
[17]	Van Campenhout A, Van Campenhout C, Lagrou AR, et al. Impact of diabetes mellitus on the relationships between iron－，inflammatory－ and oxidative stress status[J]. Diabetes/metabolism research and reviews, 2006, 22(6) : 444-454.
[18]	Behl T, Kaur I, Goel H. Implications of the endogenous PPAR－gamma ligand, 15－deoxy－delta－12, 14－prostaglandin J2, in diabetic retinopathy[J]. Life sciences, 2016, 153 : 93-99.
[19]	Poljsak B, Šuput D. Achieving the balance between ROS and antioxidants: when to use the synthetic antioxidants[J]. Oxidative medicine and cellular longevity, 2013, 2013 : 956792.
[20]	Sharma P, Jha AB, Dubey RS, et al. Reactive oxygen species, oxidative damage, and antioxidative defense mechanism in plants under stressful conditions[J]. Bot. 2012, 2012 : 217037.
[21]	Osborne NN, Casson RJ, Wood JPM, et al. Retinal ischemia: mechanisms of damage and potential therapeutic strategies[J]. Progress in Retinal & Eye Research, 2004, 23(1) : 91-147.
[22]	Augustin AJ, Keller A, Koch F, et al. Dick B. Effect of retinal coagulation status on oxidative metabolite and VEGF in 208 patients with proliferative diabetic retinopathy[J]. Klinische Monatsblätter für Augenheilkunde. 2001, 218(2) : 89-94.
[23]	Madsen－Bouterse SA. Oxidative stress and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives[J]. Reviews in endocrine & metabolic disorders, 2008, 9(4) : 315-327.
[24]	Osborne NN, Casson RJ, Wood JPM, et al. Retinal ischemia: mechanisms of damage and potential therapeutic strategies[J]. Progress in Retinal & Eye Research, 2004, 23(1) : 91-147.
[25]	Brownlee M. Biochemistry and molecular cell biology of diabetic complications[J]. Nature, 2001, 414(6865) : 813-820.
[26]	El－Remessy AB, Bartoli M, Platt DH, et al. Oxidative stress inactivates VEGF survival signaling in retinal endothelial cells via PI 3－kinase tyrosine nitration[J]. Journal of cell science, 2016, 129(16) : 3203.
[27]	严鸣光, 殷卫兵, 解传奇. VEGF、IL－6表达水平在糖尿病性视网膜病变患者中的差异性分析[J]. 中国实验诊断学，2017，21(12)：2119-2122.
[28]	Frombaum M, Therond P, Djelidi R, et al. Piceatannol is more effective than resveratrol in restoring endothelial cell dimethylarginine dimethylaminohydrolase expression and activity after high－glucose oxidative stress[J]. Free radical research, 2011, 45(3) : 293-302.
[29]	Paneni F, Beckman JA, Creager MA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I[J]. European heart journal, 2013, 34(31) : 2436-2443.
[30]	Pereira ER, Frudd K, Awad W. Endoplasmic reticulum (ER) stress and hypoxia response pathways interact to potentiate hypoxia－inducible factor 1 (HIF－1) transcriptional activity on targets like vascular endothelial growth factor (VEGF)[J]. The Journal of biological chemistry, 2014, 289(6) : 3352-3364.
[31]	Min JH, Yang H, Ivan M, et al. Structure of an HIF－1alpha－pVHL complex: hydroxyproline recognition in signaling[J]. Science, 2002, 296(5574) : 1886-1889.
[32]	Pawlus MR, Wang L. STAT3 and HIF1α cooperatively activate HIF1 target genes in MDA－MB－231 and RCC4 cells[J]. Oncogene, 2014, 33(13) : 1670-1679.
[33]	Boyer DS, Hopkins JJ, Sorof J, et al. Anti－Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema: Does Flavor Matter？[J]. JAMA ophthalmology, 2018, 136(3) : 269-270.
[34]	Eguchi M, Masuda H. Endothelial progenitor cells for postnatal vasculogenesis[J]. Clinical and experimental nephrology, 2007, 11(1) : 18-25.
[35]	Tepper OM, Galiano RD, Capla JM, et al. Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures[J]. Circulation, 2002, 106(22) : 2781-2786.
[36]	Liu X, Li Y, Liu Y, et al. Endothelial progenitor cells (EPCs) mobilized and activated by neurotrophic factors may contribute to pathologic neovascularization in diabetic retinopathy[J]. The American journal of pathology, 2010, 176(1) : 504-515.
[37]	Yang L, Guan H, He J, et al. VEGF increases the proliferative capacity and eNOS/NO levels of endothelial progenitor cells through the calcineurin/NFAT signalling pathway[J]. Cell biology international, 2012, 36(1) : 21-27.
[38]	Schulz RA. Calcineurin signaling and NFAT activation in cardiovascular and skeletal muscle development[J]. Developmental biology, 2004, 266(1) : 1-16.
[39]	Napoli C, Paolisso G, Casamassimi A, et al. Effects of nitric oxide on cell proliferation: novel insights[J]. Journal of the American College of Cardiology, 2013, 62(2) : 89-95.
[40]	李贞, 施彩虹, 倪卫杰. 基质金属蛋白酶抑制剂GM6001对鼠视网膜新生血管和VEGF表达的作用[J]. 上海交通大学学报(医学版)，2008，28(6)：665-668.
[41]	Verma RP. Matrix metalloproteinases (MMPs): chemical－biological functions and (Q)SARs [J]．Bioorganic & medicinal chemistry, 2007, 15(6) : 2223-2268.
[42]	Kowluru RA, Zhong Q. Matrix metalloproteinases in diabetic retinopathy: potential role of MMP－9[J]. Expert opinion on investigational drugs, 2012, 21(6) : 797-805.
[43]	Marumo T, Schini－Kerth VB. Vascular endothelial growth factor activates nuclear factor－kappaB and induces monocyte chemoattractant protein－1 in bovine retinal endothelial cells[J]. Diabetes, 1999, 48(5) : 1131-1137.
[44]	Kim I, Moon SO, Kim SH, et al. Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM－1), vascular cell adhesion molecule 1 (VCAM－1), and E－selectin through nuclear factor－kappa B activation in endothelial cells[J]. The Journal of biological chemistry, 2001, 276(10) : 7614-7620.
[45]	Noda K, Nakao S, Ishida S. Leukocyte adhesion molecules in diabetic retinopathy[J]. Journal of ophthalmology, 2012, 2012 : 279037.
[46]	Yoshida S, Yoshida A, Ishibashi T, et al. Role of MCP－1 and MIP－1alpha in retinal neovascularization during postischemic inflammation in a mouse model of retinal neovascularization[J]. Journal of leukocyte biology, 2003, 73(1) : 137-144.
[47]	Sennlaub F, Valamanesh F, Vazquez－Tello A, et al. Cyclooxygenase－2 in human and experiemntal ischemic proliferative retinopathy[J]. Circulation, 2003, 108(2) : 198-204.
[48]	Zhang W, Liu H, Rojas M, et al. Anti－inflammatory therapy for diabetic retinopathy[J]. Immunotherapy, 2011, 3(5) : 609-628.
[49]	Ziemssen F, Lemmen K, Bertram B, et al. National guidelines for treatment of diabetic retinopathy: Second edition of the national guidelines for treatment of diabetic retinopathy[J]. Ophthalmologe, 2016, 113(7) : 623-638.
[50]	Park YG. New Diagnostic and Therapeutic Approaches for Preventing the Progression of Diabetic Retinopathy[J]. Journal of diabetes research, 2016, 2016 : 1753584.
[51]	Tost F, Kempin R, Grossjohann R. Diabetic retinopathy－－Current aspects of therapy[J]. Medizinische Monatsschrift fuür Pharmazeuten, 2016, 39(4) : 148-156.
[52]	Nicholson BP. A review of clinical trials of anti－VEGF agents for diabetic retinopathy[J]. Graefe's archive for clinical and experimental ophthalmology ＝ Albrecht von Graefes Archiv fu？r klinische und experimentelle Ophthalmologie, 2010, 248(7) : 915-930.
[53]	Salam A, Mathew R. Treatment of proliferative diabetic retinopathy with anti－VEGF agents[J]. Acta ophthalmologica, 2011, 89(5) : 405-411.

Please choose a citation manager

Content to export